What You Should Know About Antibodies
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

What You Should Know About Antibodies

By Pharma Tech Outlook | Thursday, January 21, 2021

Antibodies are developed as a part of the immune system due to infection by viruses and bacteria.

FREMONT, CA : Antibodies are fascinating proteins. They are naturally created as part of the immune system in response to infection by viruses or bacteria and protect against the production of other diseases, like cancer. With exceptionally high affinity and specificity, antibodies often connect to the target, resulting in them being formed as special research tools.

What are Antibodies?

Proteins that belong to a family of proteins called immunoglobulins (lgs) are antibodies (Abs). Lymphocytes develop antibodies naturally, generally in response to infection by microorganisms like bacteria or viruses, and are an essential part of the immune system. A kind of protein called immunoglobulin G is the most common antibody developed by humans (IgG). Antigens are linked to the molecules that antibodies identify and bind to. There is an exact and compelling antibody-antigen interaction.

Monoclonal Antibodies

Monoclonal antibodies are produced from a single clone of B cells and show only one segment in the Immunoglobulin variable region and connect to only one epitope. Georges Köhler and César Milstein created the first hybridoma in 1975.

Initially, monoclonal antibodies were produced in mice. Mouse B cell clones are merged to myeloma cells following immunization, thus becoming immortal. The hybridomas are then evaluated for specificity and tested. To increase the development of antibodies, unique hybridomas can be cloned and extended. Mice are still generally utilized for monoclonal development, but rabbits or other mammals often develop monoclonal antibodies.

How are Monoclonal Antibodies Made?

To enhance antibody consistency and availability, the initial concept that led to the development of monoclonal antibodies was to generate antibodies in vitro consistently. The idea was to fuse the splenocytes from the immunized mice to myeloma cells by Georges Köhler and César Milstein, thereby producing hybridoma cells. Myeloma cells are expected to generate antibodies and are immortal, which means they can multiply forever and thus be a sustainable and scalable source of antibodies for hybridomas.

Weekly Brief

Read Also